Catalog No.
Product Name
Application
Product Information
Citations
-
STING Agonist
STING agonist-44 is a potent and selective agonist targeting the STING pathway. With an EC50 value of 5.68 µM for IRF induction in THP1 cells and 2.212 µM in RAW cells, this compound effectively stimulates the production of type I interferons and pro-inflammatory cytokines, such as CXCL10 and TNFα. STING agonist-44 is a valuable tool for research into cancer immunotherapy and related inflammatory conditions. -
STING Agonist
STING agonist-9 is a potent agonist of the STING (Stimulator of Interferon Genes) pathway, exhibiting an EC50 of 1.2 nM for human STING and 32.82 μM for mouse STING. This compound is known for its significant antitumor activity, making it a valuable tool for investigating immune responses in cancer research. STING agonist-9 is applicable in studies focused on immune activation and tumor microenvironment modulation. -
STING Modulator
STING modulator-5 is an inhibitor of the stimulator of interferon genes (STING) pathway, displaying a pIC50 value of 9.5. This compound effectively antagonizes peripheral blood mononuclear cells (PBMC) with a pIC50 of 8.1 and demonstrates activity against THP-1 cells. STING modulator-5 is a valuable tool for studying immunological diseases and exploring therapeutic avenues targeting STING-related signaling pathways. -
STING Inhibitor
STING modulator-3 is a selective STING inhibitor that targets the R232 variant of STING, exhibiting an inhibition constant (Ki) of 43.1 nM in scintillation proximity assays. This compound does not influence IRF-3 activation or TNF-β induction in THP-1 cells, making it a valuable tool for studying STING-mediated signaling pathways and their implications in immune responses and inflammatory diseases. Its specificity and potency provide researchers with a resource for exploring STING-related mechanisms in various biological contexts. -
STING Agonist
Parent CDN is a cyclic dinucleotide that acts as a Stimulator of Interferon Genes (STING) agonist. It has demonstrated significant anti-tumor activity by enhancing the innate immune response. This compound is utilized in research aimed at understanding immune modulation and cancer immunotherapy. -
STING Agonist
SAP-04 is a potent STING agonist that activates the stimulator of interferon genes pathway, enhancing innate immune responses. This compound demonstrates significant immunomodulatory effects, making it a valuable tool in cancer therapy research. Its oral bioactivity provides convenience for in vivo studies, facilitating the exploration of immune-mediated mechanisms in tumor immunology. -
STING Agonist
(S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide is a potent STING (stimulator of interferon genes) agonist. It exhibits a significant inhibitory effect on 3H-cGAMP binding to STING, with an IC50 value of 14 μM. This compound is valuable for research applications in tumor biology and immune response modulation, particularly in the context of cancer immunotherapy. -
hSTING Modulator
Clonixeril (NSC 335504) is a non-nucleotide modulator of human STING (hSTING), exhibiting a unique dual mechanism of action. It acts as a weak agonist at micromolar concentrations while demonstrating antagonistic properties of the hSTINGWT pathway at low femtomolar and attomolar levels. Clonixeril effectively reduces hSTING oligomerization, proving useful in elucidating the complexities of STING signaling and its role in immune responses. This compound serves as a valuable tool for research in immunology and drug discovery targeting STING-related pathways. -
STING Agonist
STING agonist-29 is a small-molecule agonist targeting the stimulator of interferon genes (STING). This compound demonstrates the ability to activate the STING pathway, leading to the induction of type I interferons and pro-inflammatory cytokines. It is particularly notable for its antiviral activity against SARS-CoV strains, making it a valuable tool for research focused on innate immunity and viral infection responses. -
STING Agonist
STING Agonist-43 is a selective STING (Stimulator of Interferon Genes) agonist that activates the cGAMP-dependent STING signaling pathway, with an EC50 of 20.53 μM. This compound enhances STING oligomerization, leading to increased activation and subsequent immune response. In preclinical studies, STING agonist-43 demonstrated antitumor efficacy in a mouse melanoma model, making it a valuable tool for investigating cancer immunity and the potential for immunotherapeutic strategies. -
STING Agonist
STING agonist-34 is a potent stimulator of the STING pathway, exhibiting an IC50 value of 1.15 μM and an EC50 value of 0.38 μM in THP1 cells. This compound activates the cGAS-STING signaling pathway, promoting type I interferon production and enhancing immune responses. STING agonist-34 is applicable in cancer research and immunotherapy studies, offering potential insights into tumor microenvironments and therapeutic strategies against malignancies. -
STING Agonist
STING agonist-25 (CF505) is a non-nucleotide small-molecule activator of the Stimulator of Interferon Genes (STING). This compound enhances the phosphorylation of STING, TBK1, and IRF3, leading to elevated levels of pro-inflammatory cytokines such as IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-25 shows potential in antiviral research, particularly against strains of SARS-CoV. -
STING Activator
STING agonist-10 is a potent small molecule cyclic urea that activates the Stimulator of Interferon Genes (STING) pathway, with an EC50 of 2600 nM. This compound enhances the immune response by stimulating the production of type I interferons, making it a valuable tool in immunotherapy research. Its ability to modulate STING activity holds potential for applications in the treatment of various cancers and infectious diseases. -
STING Agonist
BSP16 is a potent agonist of stimulator of interferon genes (STING), functioning through selective activation of the STING pathway. It exhibits significant biological activity in promoting immune responses, making it a valuable tool for cancer research and immunotherapy studies. BSP16 enables researchers to explore the therapeutic potential of STING activation in various malignancies. -
STING Agonist
STING agonist-48 is a selective agonist that activates the Stimulator of Interferon Genes (STING) pathway, demonstrating an EC50 value of 4.02 μM in vitro. It preferentially binds to the transmembrane domain, influencing downstream immune responses. This compound enhances immunogenicity by promoting IgG and Th1/Th2 cytokine responses in humanized STING mice, making it a valuable tool for investigating inflammation-related diseases and potential adjuvant therapies. -
STING Agonist
STING agonist-21 is a potent STING agonist that demonstrates an EC50 of 592.8 nM. It is designed to activate the stimulator of interferon genes (STING) pathway, which plays a crucial role in immune response modulation. This compound is primarily utilized in cancer research to investigate its effects on tumor immunity and potential therapeutic applications in oncological therapies. -
STING Agonist
Ulevostinag (isomer 2) is a selective STING (Stimulator of Interferon Genes) agonist. It activates the STING pathway, leading to enhanced production of type I interferons and pro-inflammatory cytokines. This compound is primarily utilized in research focused on cancer immunotherapy, infectious diseases, and autoimmune disorders to investigate the therapeutic potential of STING activation in modulating immune responses. -
STING Agonist
STING agonist-38 is a potent agonist of the stimulator of interferon genes (STING), demonstrating an EC50 of 0.05 μM in THP1 cells. This compound exhibits notable oral bioactivity and can effectively activate STING-mediated immune responses. It is valuable for research in immuno-oncology and pathogen response studies. -
STING Modulator
STING modulator-7 is a potent modulator of the stimulator of interferon genes (STING), enhancing the signaling pathway associated with innate immune responses. This compound exhibits significant biological activity in activating STING-dependent pathways, promoting type I interferon production and immune cell activation. It is primarily utilized in research applications focused on cancer immunotherapy, infectious disease models, and studies of immune system regulation. -
STING Agonist
Ulevostinag (isomer 3) is a potent STING (Stimulator of Interferon Genes) agonist that functions through the activation of the STING pathway, leading to the induction of type I interferons and other cytokines. This compound has demonstrated significant biological activity in promoting anti-tumor immune responses, making it an essential tool for cancer immunotherapy research. Its ability to modulate immune signaling pathways positions Ulevostinag (isomer 3) as a valuable reagent in the study of immune activation and anti-cancer strategies. -
STING Agonist
Ulevostinag (isomer 4) is a potent STING (Stimulator of Interferon Genes) agonist that activates the STING signaling pathway, leading to the production of type I interferons and other pro-inflammatory cytokines. This compound enhances the immune response, making it valuable for research in cancer immunotherapy and infectious disease. Ulevostinag (isomer 4) serves as an important tool for studying STING-mediated pathways and their role in immune modulation. -
TpoR Agonist
Totrombopag is an orally active thrombopoietin receptor (TpoR) agonist. It activates TpoR, triggering an intracellular signaling cascade involving JAK2 kinase and the transcription factor Stat5, which is crucial for the regulation of megakaryocyte growth and differentiation into platelets. This compound is valuable for research into platelet production and the biology of megakaryocytes. -
TpoR Agonist
Totrombopag choline is a potent thrombopoietin receptor (TpoR) agonist that effectively stimulates megakaryocyte growth and platelet production. By activating TpoR, it triggers a signaling cascade involving JAK2 kinase and Stat5, which plays a crucial role in megakaryocyte differentiation. This compound is valuable for research focused on platelet biology and the mechanisms regulating thrombopoiesis. -
TLR7 Agonist
SMU-L11 is a selective TLR7 agonist with an EC50 of 0.024 μM, which engages the MyD88 adapter protein to activate downstream NF-κB and MAPK signaling pathways. This compound significantly enhances immune cell activation in murine models, promoting the proliferation of CD4+ T and CD8+ T cells, leading to direct tumor cell lysis and inhibition of tumor growth. SMU-L11 is a valuable reagent for cancer research and can also be utilized for investigations into immune system-related diseases. -
TLR4/HCN Inhibitor
HCN-IN-1 is a TLR4 inhibitor and modulator of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, specifically targeting HCN2 and HCN4. It effectively inhibits TLR4-mediated signaling, evidenced by reduced alkaline phosphatase activity. HCN-IN-1 modulates HCN2 currents by shifting the voltage-dependent activation to hyperpolarized potentials and slowing activation kinetics, while also blocking currents through HCN4 channels. This compound demonstrates significant analgesic, anti-inflammatory, and anti-anginal properties, making it valuable for research into inflammatory pain, neuropathic pain, heart failure, and related inflammatory conditions. -
Anti-CD33 Antibidy
Vadastuximab is a humanized monoclonal antibody that selectively targets CD33, a cell surface protein predominantly expressed on myeloid cells and acute myeloid leukemia (AML) cells. This antibody is instrumental in the development of antibody-drug conjugates (ADCs) designed for targeted therapeutic applications. Research indicates that Vadastuximab can enhance the efficacy of cancer treatments by delivering cytotoxic agents directly to CD33-expressing tumors, thereby promoting precise tumor eradication while minimizing off-target effects. -
CD33 Splicing Modulator
CD33 Splicing Modulator 1 is an innovative agent that targets the CD33/Siglec 3 receptor, a crucial regulator of microglial activity in the myeloid lineage. This compound enhances exon 2 skipping in cellular mRNA, thereby altering CD33 expression. It holds promise as a research tool in neurodegenerative disease studies, particularly in the context of Alzheimer's disease, facilitating a deeper understanding of the underlying mechanisms of these conditions. -
FKBPL Peptide
AD 01 is a 24-amino acid peptide derived from FKBPL (FK506-binding protein like), targeting the CD44 receptor to exert significant anti-angiogenic effects. By binding to CD44, AD 01 effectively inhibits tumor cell migration in a manner dependent on this receptor. This peptide is valuable for research applications focused on cancer biology, particularly in studies related to angiogenesis and tumor metastasis. -
MR1 Antigen
Photolumazine III is an MR1 (MHC class I-related molecule 1) antigen, which plays a crucial role in the immune response by presenting antigenic metabolites to T cells. This compound exhibits biological activity related to the activation of MR1-restricted T cell responses, thus serving as a valuable tool for studying immune mechanisms and developing immunotherapies. Research applications include the investigation of microbial and tumor-associated antigens, as well as the modulation of immune responses in various disease models. -
Anti-EpCAM/TROP1/CD326 Antibody
Varsetatug is a humanized IgG1κ monoclonal antibody that targets the epithelial cell adhesion molecule (EpCAM), also known as TROP1 or CD326. This antibody exhibits significant antitumor activity, making it a valuable tool for studying various malignancies, including breast, prostate, and ovarian cancers. Varsetatug is instrumental in cancer research, particularly in investigating therapeutic approaches that exploit EpCAM pathways. -
CD8 T Cell Epitope
TYVPANASL is a MHC I-binding CD8 T cell epitope derived from the HER2/neu protein. This nine-amino-acid peptide plays a crucial role in stimulating CD8 T cell responses, making it valuable in immunological studies and vaccine development. TYVPANASL can be utilized in the preparation of J-LEAPS vaccines, contributing to cancer immunotherapy research. -
CD36 Ligand
KDdiA-PC is a highly potent ligand for CD36, primarily targeting the receptor that mediates the cellular response to oxidized low-density lipoprotein (oxLDL). Its significant biological activity facilitates studies on lipid metabolism, inflammation, and atherosclerosis. KDdiA-PC is valuable for researchers investigating the role of CD36 in various physiological and pathological processes. -
CD63-binding Peptide
CP05 is a CD63-binding peptide that specifically interacts with the exosome surface marker CD63. This interaction facilitates the anchoring of exosomes to target tissues, enhancing in vivo delivery of exosomal payloads. CP05 is useful in research applications focused on drug delivery, therapeutic targeting, and the study of exosome biology. -
CD36 Peptide
CD36 Peptide P (139-155), Cys conjugated targets the CD36 protein and serves as a crucial tool for studying its function. This Cys-conjugated peptide is effective in inhibiting the immunoadsorption of CD36 by the OKM5 antibody, making it valuable for research applications focused on immune responses and metabolic processes. The peptide can aid in the investigation of CD36-related pathways and its role in various biological contexts. -
Anti-PD-1/TIGIT Antibody
Nilvanstomig is an anti-PD-1/TIGIT antibody that targets the PD-1/TIGIT pathway, thereby facilitating T cell activation and enhancing natural killer (NK) cell anti-tumor activity. This compound is particularly relevant in the study of advanced cervical cancer and contributes to research focused on immune modulation and cancer immunotherapy. Its mechanism of action underscores its potential for strengthening anti-tumor responses in various oncological contexts. -
CD36 Peptide
CD36 Peptide P (93-110), Cys conjugated specifically targets CD36, a multifunctional receptor involved in cellular adhesion and lipid metabolism. This peptide has been shown to block the binding of CD36 to immobilized thrombospondin, thereby providing valuable insights into CD36-mediated pathways. Additionally, it partially inhibits collagen-induced platelet aggregation, making it useful for research applications related to cardiovascular function and cell signaling. -
Anti-CD326/EPCAM Antibody
Anti-CD326/EPCAM Antibody (3622W94) is a humanized antibody that specifically targets the epithelial cell adhesion molecule (EpCAM/CD326), a key player in cell-cell adhesion and signaling. This antibody is suitable for research applications focused on various epithelial cancers, including pancreatic, prostate, and breast cancer. Its ability to interfere with tumor progression and metastasis makes it a valuable tool for studies in cancer biology and therapeutic development. -
Anti-CEACAM5/CEA/CD66e Antibody
Altumomab is a human monoclonal antibody that selectively targets CEACAM5 (carcinoembryonic antigen, CEA) and CD66e. This antibody is primarily utilized in cancer research, particularly for tumor identification and immunotherapy applications. Its specificity for CEACAM5 makes it a valuable tool in the study of various malignancies, enabling enhanced detection and therapeutic strategies against CEA-expressing tumors. -
CD33 Splicing Modulator
CD33 splicing modulator 1 hydrochloride is a small molecule modulator that targets CD33/Siglec 3, a myeloid cell surface receptor that regulates microglial activity. This compound promotes exon 2 skipping in cellular mRNA, making it a valuable tool for investigating the molecular mechanisms underlying neurodegenerative diseases, particularly Alzheimer's disease. It provides researchers with a means to explore potential therapeutic approaches through modulation of splicing events related to CD33. -
COX Inhibitor
SC57666 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 26 nM. This compound exhibits anti-inflammatory activity by specifically blocking COX-2, thereby reducing prostaglandin synthesis. SC57666 is valuable for research applications focused on understanding inflammation and pain mechanisms, as well as for screening in drug discovery efforts targeting COX-2 related conditions. -
COX Inhibitor
FR-188582 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 17 nM. This compound exhibits potent anti-inflammatory activity, making it a valuable tool for studies related to pain and inflammation pathways. Its specificity for COX-2 allows for the exploration of therapeutic applications in conditions such as arthritis and other inflammatory diseases. -
COX Inhibitor
Nitroflurbiprofen is a cyclooxygenase (COX) inhibitor known for its nitric oxide (NO)-donating properties. It effectively modulates increased intrahepatic vascular tone, making it a valuable tool in studying portal hypertension and liver diseases. This compound is utilized in research contexts focused on the therapeutic mechanisms of COX inhibition and its impact on hepatic vascular dynamics. -
Anti-Inflammatory Agent
Apyramide is an anti-inflammatory agent that acts as a prodrug of indomethacin. It serves as a potent and nonselective inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting significant blood-brain barrier permeability. Apyramide is primarily utilized in research applications focused on inflammation modulation and pain relief. -
COX Inhibitor
RWJ 63556 is an orally active inhibitor of cyclooxygenase-2 (COX-2) and a 5-lipoxygenase inhibitor, exhibiting significant anti-inflammatory properties. This compound is utilized in research to explore its potential therapeutic effects in conditions characterized by inflammation, such as arthritis and other inflammatory diseases. Its selective inhibition may provide insights into the role of COX-2 and lipoxygenase pathways in various biological processes. -
Anti-inflammatory agent
Ketoprofen (lysinate) is a non-steroidal anti-inflammatory agent primarily targeting cyclooxygenase enzymes. It exhibits potent inhibitory activity with IC50 values of 2 nM for COX-1 and 26 nM for COX-2. This compound is valuable for research applications in inflammation, immunology, and metabolic diseases such as obesity, making it an essential tool for exploring pathways in these biological contexts. -
COX Inhibitor
COX-2-IN-6 is a selective cyclooxygenase-2 (COX-2) inhibitor, specifically designed for oral administration and exhibiting gut-restricted properties. With an IC50 value of 0.84 μM and a Ki of 69 nM, COX-2-IN-6 effectively targets COX-2, inhibiting COX-2-driven PGE2 synthesis with an IC50 of 0.60 μM. This compound is utilized in research focused on colorectal cancer chemoprevention, offering valuable insights into inflammatory processes and therapeutic strategies. -
COX-2 Inhibitor
COX-2-IN-28 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 0.054 µM for COX-2, while demonstrating significantly lower inhibitory activity against 15-lipoxygenase (2.14 µM) and cyclooxygenase-1 (13.21 µM). This selective inhibition positions COX-2-IN-28 as a valuable tool for investigating the role of COX-2 in inflammation and pain pathways. It is suitable for research applications focused on inflammatory diseases and therapeutic development targeting COX-2 pathways. -
COX Inhibitor
Tolmetin sodium is a potent inhibitor of cyclooxygenase (COX), demonstrating IC50 values of 0.35 μM for human COX-1 and 0.82 μM for COX-2. As a non-steroidal anti-inflammatory drug (NSAID), it is primarily used for its analgesic and anti-inflammatory properties. Tolmetin sodium is valuable in research applications focused on pain management, inflammation, and associated disorders. -
Anti-inflammatory Compound
Amfenac sodium is an orally active anti-inflammatory compound known for its potent analgesic and antipyretic properties. It acts by inhibiting the cyclooxygenase enzymes, thereby reducing inflammatory responses. This reagent is valuable for research applications related to both acute and chronic inflammation, facilitating a deeper understanding of inflammatory pathways and potential therapeutic interventions. -
COX-2 Inhibitor
SD 8381 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2). It demonstrates an IC50 value of 0.0098 μM against human COX-2 and 0.69 μM against human COX-1, indicating a high degree of selectivity. This compound is valuable for research applications focused on inflammation and pain management, as well as studies examining the role of COX-2 in various disease states.
